Skip to main content
. 2019 Jul 19;5(2):151–163. doi: 10.1007/s41030-019-0096-8

Table 5.

Treatment-emergent adverse events in ≥ 10% of patients in the safety-evaluable population

TEAE, n (%) Vismodegib 150 mg/day + pirfenidone ≤ 2403 mg/day (N = 21)
Total 21 (100)
Muscle spasms 16 (76.2)
Dysgeusia 13 (61.9)
Alopecia 7 (33.3)
Weight loss 7 (33.3)
Decreased appetite 6 (28.6)
IPF 3 (14.3)
Nausea 3 (14.3)

IPF idiopathic pulmonary fibrosis, TEAE treatment-emergent adverse event